Monoclonal antibodies (mAbs) are well established in the clinic due to their specificity and
affinity to a diverse array of biochemical targets. More recently, mAbs are being exploited as …

Immunoconjugates—monoclonal antibodies (mAbs) coupled to highly toxic agents,
including radioisotopes and toxic drugs (ineffective when administered systemically alone) …

Standard cancer therapies sometimes fail to deliver chemotherapeutic drugs to tumor cells
in a safe and effective manner. Nanotechnology takes the lead in providing new therapeutic …

Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …

Conventional anticancer therapeutics often suffer from lack of specificity, resulting in poor
therapeutic indexes and substantial toxicities to normal healthy tissues. Monoclonal …

Much progress has been made during the last few decades in the treatment of malignancies.
Many types of cancer cells comprising the tumor mass carry molecular markers that are not …

Recent advances in nanomedicine have shown that dramatic improvements in nanoparticle
therapeutics and diagnostics can be achieved through the use of disease specific targeting …

The field of targeted therapeutics has benefitted immeasurably from the development of high-
affinity antibodies. These important ligands have facilitated the development of effective …

A great challenge to clinical development is the delivery of chemotherapeutic agents, known
to cause severe toxic effects, directly to diseased sites which increase the therapeutic index …

Proteins have sparked fast growing interest as biological therapeutic agents for several
diseases. Antibodies, in particular, carry an enormous potential as drugs owing to their …